Regeneron Pharmaceuticals (REGN) – Analysts’ Weekly Ratings Updates

Regeneron Pharmaceuticals (NASDAQ: REGN) recently received a number of ratings updates from brokerages and research firms:

• 11/15/2024 – Regeneron Pharmaceuticals is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $1,150.00 price target on the stock.
• 11/14/2024 – Regeneron Pharmaceuticals was upgraded by analysts at Wolfe Research to a “strong-buy” rating.
• 11/14/2024 – Regeneron Pharmaceuticals is now covered by analysts at Citigroup Inc.. They set a “neutral” rating and a $895.00 price target on the stock.
• 11/13/2024 – Regeneron Pharmaceuticals was upgraded by analysts at Citigroup Inc. to a “hold” rating.
• 11/6/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Oppenheimer Holdings Inc. from $1,150.00 to $1,000.00. They now have an “outperform” rating on the stock.
• 11/4/2024 – Regeneron Pharmaceuticals was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 11/1/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Morgan Stanley from $1,235.00 to $1,184.00. They now have an “overweight” rating on the stock.
• 11/1/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Barclays PLC from $1,080.00 to $1,065.00. They now have an “overweight” rating on the stock.
• 11/1/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Piper Sandler from $1,242.00 to $1,195.00. They now have an “overweight” rating on the stock.
• 11/1/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Royal Bank of Canada from $1,260.00 to $1,215.00. They now have an “outperform” rating on the stock.
• 11/1/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $1,300.00 to $1,190.00. They now have an “outperform” rating on the stock.
• 11/1/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Truist Financial Co. from $1,137.00 to $1,126.00. They now have a “buy” rating on the stock.
• 10/24/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $1,200.00 to $1,150.00. They now have an “overweight” rating on the stock.
• 10/24/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Evercore ISI from $1,250.00 to $1,175.00. They now have an “outperform” rating on the stock.
• 10/23/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Barclays PLC from $1,220.00 to $1,080.00. They now have an “overweight” rating on the stock.
• 10/23/2024 – Regeneron Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $1,015.00 price target on the stock.
• 10/22/2024 – Regeneron Pharmaceuticals was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 10/22/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Wells Fargo & Company from $1,200.00 to $1,050.00. They now have an “overweight” rating on the stock.
• 10/22/2024 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $1,260.00 price target on the stock.
• 10/16/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Truist Financial Co. from $1,200.00 to $1,137.00. They now have a “buy” rating on the stock.
• 10/9/2024 – Regeneron Pharmaceuticals was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ:REGN traded down $12.77 on Wednesday, hitting $749.57. 649,997 shares of the company’s stock were exchanged, compared to its average volume of 544,991. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The stock has a market capitalization of $82.37 billion, a price-to-earnings ratio of 18.55, a price-to-earnings-growth ratio of 2.94 and a beta of 0.08. The business’s 50 day simple moving average is $893.12 and its two-hundred day simple moving average is $1,016.56. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Brown Lisle Cummings Inc. lifted its position in shares of Regeneron Pharmaceuticals by 18.2% during the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 10 shares during the last quarter. Sachetta LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Adirondack Trust Co. raised its holdings in shares of Regeneron Pharmaceuticals by 2.4% in the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after acquiring an additional 10 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after acquiring an additional 10 shares in the last quarter. Finally, Western Financial Corp CA raised its holdings in shares of Regeneron Pharmaceuticals by 0.7% in the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock valued at $1,912,000 after acquiring an additional 12 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.